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Objective: To investigate the effect-enchancing and toxicity-reducing action of the extract of Ban Zhi Lian 
(ञᵱ㦆 Herba Scutellariae Barbatae, EHSB) for chemotherapy in hepatoma H22 tumor-bearing mice. 
Methods: The tumor-bearing mice were divided into 6 groups randomly: a model group, a high dose EHSB 
group, a low dose EHSB group, a 5-fluorouracil (5-FU) group, a 5-FU+high dose EHSB group and a 
5-FU+low dose EHSB group, and with a normal group set as the controls. All the groups were treated for 10 
days. The life prolongation rate, toxic reactions of chemotherapy, WBC count, the body weight, tumor weight, 
thymus index and spleen index, and phagocytic function of intra-abdominal macrophages were investigated 
in the H22 tumor-bearing mice. Results: The increase of the body weight in both the 5-FU+EHSB groups 
was significantly higher than that in the 5-FU group, with the toxic reactions such as anorexia, abdominal 
distension and emaciation significantly alleviated. Growth of the tumor was significantly inhibited in the 
high dose EHSB group, the 5-FU group, the 5-FU+high dose EHSB group, and the 5-FU+low dose EHSB 
group. The survival time in the 5-FU+high dose EHSB group and the 5-FU+low dose EHSB group was 
significantly prolonged as compared with that of the 5-FU group. The life prolongation rate was 98.72% in 
the 5-FU+high dose EHSB group and 52.11% in the 5-FU+low dose EHSB group. Growth of the 
transplanted tumor was significantly inhibited in the high dose EHSB group, the 5-FU group, the 5-FU+high 
dose EHSB group, the 5-FU+low dose EHSB group. The tumor inhibition rate in the high dose EHSB group, 
the 5-FU group, the 5-FU+high dose EHSB group and the 5-FU+low dose EHSB group was 36.98%, 42.26%, 
65.28% and 52.45%, respectively. 5-FU combined with a high-dose EHSB could significantly enhance the 
tumor inhibition rate (P<0.05). The thymus index and the spleen index significantly increased in the high 
dose EHSB group, and atrophy of the immunological organs induced by chemotherapy was improved in the 
5-FU+high dose EHSB group and in the 5-FU+low dose EHSB group. The WBC count decreased 
significantly in the 5-FU group, but increased in both the 5-FU+EHSB groups. The phagocytic function of 
intra-abdominal macrophages was increased in both the 5-FU+EHSB groups, with the phagocytic rate and 
the phagocytic index increased by 78.55% and 81.63% in the 5-FU+high dose EHSB group and by 43.97% 
and 44.90% in the 5-FU+low dose EHSB group. Conclusions: EHSB can significantly enhance the tumor 
inhibition rate of 5-FU, reduce the toxic effects, prolong the survival time, and improve immune function in 
the H22 tumor-bearing mice. 
Recent studies have demonstrated that Ban Zhi Lian 
(ञᵱ㦆 Herba Scutellariae Barbatae, HSB) has a 
good anti-tumor effect, which can be used for 
treatment of primary liver cancer, lung cancer and 
carcinoma of the uterine cervix, and when in 
combination with other Chinese medicine compounds 
it is indicated for more kinds of cancers.1-3 At present, 
the toxicity-reducing and effect-enhancing action of 
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Chinese medicine for radiotherapy and chemotherapy 
of tumors have been confirmed. 4-6 The present 
experiment was designed to investigate the 
anti-tumor effect of EHSB combined with 5- 
fluorouracil (5-FU), so as to probe the effect- 
enhancing and toxicity-reducing action for 
chemotherapy in H22 tumor-bearing mice. 
MATERIALS AND METHODS 
Extract of Herba Scutellariae Barbatae (EHSB, Xi’an 
Zhongxin Biotechnology Co. Ltd.); 5-fluorouracil 
(5-FU, Shanghai Xudong Haipu Pharmaceutical Co. 
Ltd); the other reagents are analytical pure made in 
China. ICR mice, weighing 20±2 g, male and female 
in half, supplied by Animal Center of Xi’an Jiaotong 
University (No.08-004). The mouse hepatoma H22 
cell strain was preserved in College of Life Sciences, 
Shanxi Normal University. 
Modelling of the tumor-bearing mice 
Ascites was taken from hepatoma H22 mice passing 
on from generation to generation for 6-7 days under 
aseptic condition, which was diluted with normal 
saline into a suspended solution in a concentration of 
1x107 cells/ml. For the solid tumor experiment, 0.2 
ml of the cell suspension was injected into the 
subcutaneous part of the right axillary fossa in each 
mouse, and for the ascites tumor experiment, 0.2 ml 
of the cell suspension was injected into the 
abdominal cavity in each mouse. 
Grouping and administration 
Twenty-four hours after injection of the H22 cells, 
the mice were randomly divided into 6 groups, i.e. a 
model group, a high dose EHSB group, a low dose 
EHSB group, a 5-fluorouracil (5-FU) group, a 
5-FU+high dose EHSB group and a 5-FU+low dose 
EHSB group, 10 mice in each group, and with a 
normal group set as the controls (0.2 ml saline was 
injected into the right axillary fossa for each mouse 
of this group). The mice in both the normal control 
group and the model group were given intra-gastric 
perfusion of 0.4ml saline, once a day. In the 5-FU 
group, 5-FU (0.02 g/kg) was injected into the 
abdominal cavity, once daily. The high and low dose 
EHSB groups received intra-gastric perfusion of 
EHSB at the dose of 12 g and 3 g/kg respectively 
once daily. The above treatments lasted 10 days. 24 h 
after the last administration, all the mice were killed. 
The blood sample was taken for count of WBC, and 
the tumor was separated and weighed. The tumor 
inhibition rate was calculated: (the tumor weight of 
the model group − the tumor weight of the treatment 
group) / the tumor weight of the model group x 
100%.  
Determination of life prolongation rate in the 
H22-bearing mice 
The grouping and drug administration for the ascites 
tumor experiment were the same as the solid tumor 
experiment. The survival time of the mice was 
recorded for 35 days after the drug was withdrawn. 
The experiment would be invalid if the mortality rate 
in the control group during the experiment was ≥
20% or the survival time of 20% mice was longer 
than 4 weeks. The life prolongation rate = (the mean 
living days of the mice in the treatment group / the 
mean living days in the control group −1) x 100%. 
Determination of the thymus index and spleen 
index 
After the tumor inhibition experiment in the mice 
with solid tumor was ended, the mice in each group 
were sacrificed. The thymus and spleen were taken 
and weighted, and the thymus index and the spleen 
index were calculated. The thymus index = the 
thymus weight (mg) / body weight (g); while the 
spleen index = the spleen weight (mg) / body weight 
(g). 
Assessment of the phagocytic function of 
intra-abdominal macrophages 
One day before the last administration, 1 ml of 5% 
chicken erythrocyte suspension was injected into the 
abdominal cavity of each mouse. 24 hours later, all 
the mice were sacrificed, and 2 ml normal saline was 
injected into the abdominal cavity of each mouse 
through the peritoneum with the median abdominal 
skin incised. After that, the abdomen of each mouse 
was kneaded, the abdominal liquid was sucked and 
dropped on a slide, and incubated at 37ć for 30 min, 
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then washed with saline, fixed with acetone-methanol 
solution (1:1) for 5 min, stained with 4% giemsa for 3 
min, rinsed with running water and dried. Ten 
consecutive high power fields were taken for 
calculating the phagocytic rate and the phagocytic 
index. The phagocytic rate (%) = (The macrophages 
phagocytizing RBC / the total macrophages) x 100%; 
and the phagocytic index = the phagocytized chicken 
erythrocytes / the total macrophages.  
Statistical analysis 
The data were expressed as mean ± standard 
deviation (SD). SPSS11.0 software was used for q
test in single factor analysis of variance to evaluate 
the differences between two groups, with α = 0.05 
regarded as a significant difference. 
RESULTS 
Effect of EHSB on body weight and general 
conditions in H22 tumor-bearing mice 
The body weight of the tumor-bearing mice in all the 
groups increased in varying degrees. The body 
weight increase was significantly higher in the high 
dose EHSB group than that of the model group 
(P<0.05); but the increase in the 5-FU group was 
significantly lower than those of the other groups. 
The increase in the 5-FU+EHSB groups was 
significantly higher than that of the 5-FU group (see 
Table 1).  
The movement gradually became slower in the mice 
of the model group, with trichoxerosis, less eating 
and drinking and slow increase of body weight; and 
the mice in the 5-FU group even died in the course of 
administration. In contrast, the mice in the EHSB 
groups were vigorous with flourishing hair, rapid 
increase of the body weight, showing a good general 
condition. The toxic responses in the 5-FU group 
were also serious, manifested by anorexia, abdominal 
distention, listlessness and emaciation, etc.; while the 
mice in the EHSB groups showed no such the 
symptoms, and the mice in the 5-FU+EHSB groups 
showed milder adverse effects with no obvious 
anorexia, abdominal distention and emaciation, etc.
Table 1. Effect of EHSB on body weight in H22 tumor-bearing mice ( x fs, n=10) 
Body weight (g) 
Group Dosage (g/kg/d)
Pre-treatment Post-treatment
Increase of body weight (g)
Model - 20.03±2.07 23.50±3.24 3.47±3.82#
 3.00 20.00±1.94 24.52±1.82 4.52±3.93#
EHSB 
12.00 20.01±2.10 25.15±2.13  5.14±3.76*#
5-FU  0.02 19.96±2.03 20.74±1.86 0.78±1.93* 
0.02+3.00 20.00±2.13 22.46±1.92 2.46±1.62#5-FU+EHSB
 0.02+12.00 19.98±2.05 20.74±2.05  4.35±3.25*#
Control - 20.03±1.94 24.12±2.02 4.09±2.32#
Note: *P<0.05, vs the model grouo; #P<0.05, vs the 5-FU group.
Effects of EHSB on the life prolongation rate and 
the tumor inhibition rate in the H22 tumor- 
bearing mice 
The survival time of the ascites tumor mice in the 
high dose EHSB group was significantly higher than 
those of the model group and the 5-FU group 
(P<0.05); and the survival time of the 5-FU group 
was little shorter than that of the model group with no 
significant difference between the two groups. The 
life prolongation rates in the 5-FU+high dose EHSB 
group and the 5-FU+low dose group were 98.72% 
and 52.11% respectively, which were significantly 
higher than that of the 5-FU group (see Table 2). 
The tumor weight in the high dose EHSB group and 
the 5-FU group was significantly lower than that of 
the model group (P<0.05), with a tumor inhibition 
rate of 36.98% and 42.26%, respectively. The tumor 
inhibition rate was 14.34% in the low dose EHSB 
group, with no significant difference as compared to 
the model group (P>0.05); and the rat was 65.28% in 
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the 5-FU+high dose EHSB group, which was 
significantly higher than that of the 5-FU group 
(P<0.05). No significant difference was found 
between the 5-FU+low dose EHSB group and the 
5-FU group in the tumor inhibition rate (P>0.05), as 
showed in the Table 2.
Table 2. Effects of EHSB on the life prolongation rate and the tumor inhibition rate 
in H22 tumor-bearing mice ( x fs, n=10)
Life prolongation rate(%)Group Dosage
(g/kg/d)
Survival
time (d) vs model group vs 5-FU group
Tumor
weight (g)
Tumor
inhibition rate (%)
Model - 16.32±4.92 - - 2.65±1.12# -
 3 18.47±5.23# 13.17 39.29 2.27±0.93# 14.34EHSB
12  24.65±5.80*# 51.04 85.90 1.67±0.76* 36.98
5-FU  0.02 13.26±4.15 - - 1.53±0.64* 42.26
0.02+3 20.17±4.54# 23.59 52.11 1.26±0.45* 52.455-FU+EHSB
  0.02+12  26.35±5.65*# 61.46 98.72  0.92±0.58*# 65.28
       Note: *P<0.05, vs the model group; #P<0.05, vs the 5-FU group.
Effects of EHSB on the thymus index, spleen index 
and WBC count in H22 tumor-bearing mice 
As compared with the model group, the thymus index 
and the spleen index increased significantly in the 
high dose EHSB group (P<0.01), but decreased 
significantly in the 5-FU group. As compared with 
the normal control group, the thymus index and the 
spleen index were significantly lower in the model 
group and further decreased in the 5-FU group. In the 
5-FU+high dose EHSB group and the 5-FU+low 
dose EHSB group, atrophy of the immune organs 
induced by chemotherapy were improved. As 
compared with the model group, the WBC count 
showed no significant difference in both the EHSB 
groups (P>0.05), a significant decrease in the 5-FU 
group, and an increase tendency in the 5-FU+EHSB 
groups (see Table 3).
Table 3. Effects of EHSB on the thymus index, spleen index and WBC count  
in H22 tumor-bearing mice ( x fs, n=10) 
Group Dosage (g/kg/d) Thymus index (mg/g) Spleen index (mg/g) WBC count (109/L)
Model - 2.47±0.68# 3.82±2.32# 8.78±0.68 
3 2.62±1.54# 4.25±1.92# 8.82±0.59 
EHSB 
12 3.65±2.36* 5.44±3.06* 9.16±0.70 
5-FU 0.02 1.43±0.56*#  2.92±1.73*#  5.15±0.52* 
0.02+3 2.55±1.32# 3.96±1.65# 7.62±0.64#5-FU+EHSB
0.02+12 3.16±2.15# 4.72±2.02#  8.47±0.58#
Control -  3.64±2.03*# 5.67±2.37*# 9.08±0.74 
Note: *P<0.05, vs the model group; #P<0.05, vs the 5-FU group.
Effect of EHSB on phagocytic function of intra- 
abdominal macrophages in H22 tumor-bearing 
mice 
The phagocytic function of the intra-abdominal 
macrophages was significantly enhanced in the high 
dose EHSB group. The lowered phagocytic function 
of the intra-abdominal macrophages that may be 
induced by 5-FU treatment was improved in the 
5-FU+high dose EHSB group and the 5-FU+low 
dose EHSB group. As compared with the 5-FU group, 
the phagocytic rate was increased by 78.55% and 
43.97%, and the phagocytic index was increased by 
81.63% and 44.90% respectively in the 5-FU+high 
dose EHSB group and in the 5-Fu+low dose EHSB 
group (see Table 4).
Journal of Traditional Chinese Medicine 2008; 28(3): 205-210 209
Table 4. Effect of EHSB on phagocytic function of intra-abdominal macrophages 
in H22 tumor-bearing mice ( x fs, n=10) 
Group Dosage (g/kg/d) Phagocytic rate (%) Phagocytic index
Model - 38.52±3.16# 0.73±0.04#
3 41.32±3.05# 0.79±0.05#
EHSB
12 47.46±3.55*#  0.93±0.06*#
5-Fu 0.02 22.47±2.12* 0.49±0.03*
  0.02+3 32.35±2.53# 0.71±0.06#5-Fu+EHSB
   0.02+12 40.12±3.68# 0.89±0.05#
             Note: *P<0.05, vs the model group; #P<0.05, vs the 5-FU group.
DISCUSION 
At present, chemotherapy is usually adopted as one 
of the main measures for a comprehensive treatment 
of tumors. However, the adequate dosage in a 
complete course may induce such adverse effects as 
bone marrow suppression, gastrointestinal reactions 
and a lowered immunological function. This may 
possibly limit the adequate dosage, and decrease the 
therapeutic effects.4, 5 Now, the immuneoregulation, 
the body resistance-strengthening and anti-cancer 
effects of Chinese herbal medicines have attracted 
more and more attention. 7, 8
Traditional Chinese medicine holds that primary liver 
cancer should be attributed to the damp-heat 
pathogen protractedly attacking the human body, 
leading to a weakened body resistance and resulting 
in a lingering pathogenic course with stagnancy of qi
and blood, imbalance of yin and yang, stagnation of 
liver-qi, deficiency of spleen, and with blood stasis 
blocking the channels and collaterals, thus, forming 
tumor in the hypochondrium.7 Herba Scutellariae 
Barbatae may show the effects of clearing away heat 
and toxic materials, removing blood stasis and 
promoting urination. It has been demonstrated that 
EHSB possesses an obvious inhibitory action on the 
transplanted tumors (S180 and H22), and it can 
promote proliferation of the spleen cells in mice with 
a good dose-effect relation; 9 and the experiment in 
vitro shows that EHSB can inhibit proliferation of the 
hepatic tumor cells and induce the apoptosis.2 The 
present study indicates that in the high dose EHSB 
group, the growth of H22 transplanted tumor is 
significantly inhibited; and that the tumor inhibition 
rate in the 5-FU+high dose EHSB group is 
significantly higher than that of the 5-FU group, 
while no such significant difference was found in the 
low dose EHSB group. 
How to increase the sensitivity of tumor to 
chemotherapeutic drugs and how to reduce the side 
effects have attracted more and more attention for the 
cancer treatment. In this study, the increase of body 
weight in both the 5-FU+EHSB groups is 
significantly higher than that of the 5-FU group. The 
adverse effects, such as anorexia, abdominal 
distention, listlessness and emaciation, were found in 
the 5-FU group, but no such side effects were shown 
in both the EHSB groups; and the toxic reactions 
were markedly reduced in both the 5-FU+EHSB 
groups. The life prolongation rate is 61.46% in the 
5-Fu+high dose EHSB group and 23.59% in the 
5-Fu+low dose EHSB group; and as compared with 
that of the 5-Fu group, the rates were 98.72% and 
52.11% respectively, showing the importance of 
supporting treatment in chemotherapy. 
With development and deterioration of the malignant 
tumor, the immune function of the patient may be 
decreased, which will become more severer in the 
course of radiotherapy and chemotherapy, lower the 
therapeutic effect, or even discontinue the 
treatment.4,8 In the present study, the thymus index 
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and the spleen index obviously decreased in the mice 
of the model group, and even more decreased in the 
5-FU group; but they were significantly increased in 
the high dose EHSB group and in both the 5-FU+ 
EHSB groups, indicating that EHSB can improve the 
condition of immune organs, and decrease the 
immune response in the tumor-bearing mice induced 
by chemotherapy. And for the tumor-bearing mice 
given 5-FU, EHSB can elevate WBC count and 
enhance the phagocytic function of intra-abdominal 
macrophages, indicating that EHSB can effectively 
antagonize the immunosuppression caused by tumor. 
Therefore, EHSB may probably be used as a 
biological response modifier in chemotherapy. 
The present study shows that a high dose of EHSB 
(12g/kg/d) has a tutor-inhibiting action, show a 
certain synergism with 5-FU, and can reduce the 
toxic side effects; while the low dose of EHSB 
(3g/kg/d) can obvious reduce the toxic reactions and 
improve the immunosuppression though it can not 
elevate the tumor inhibition rate. The effect- 
enhancing and toxicity-reducing action of EHSB may 
be possibly due to the anti-tumor effect displayed by 
flovonoids and diterpenes contained in EHSB; 10 and 
its components, such as alkaloid, steroid and poly-
saccharide, may also activate the immune action of 
immune cells on the tumor cells. 
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